News for Zimmer Biomet Holdings, Inc. (ZIM.DE)

**media[647109]**

SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. ( FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of in

PR NewswireWARSAW, Ind., May 30, 2025 WARSAW, Ind., May 30, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technol

Zimmer Biomet Holdings (ZBH) declares a Q2 2025 dividend of $0.24 per share. Dividend to be paid on July 31, 2025, to shareholders of record by June 26,

Zimmer Biomet Holdings, Inc. (ZBH) has announced the appointment of Kevin Thornal to the newly-created position of Group President, Global Businesses and the

PR NewswireWARSAW, Ind., May 27, 2025 WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technol

Zimmer Biomet (ZBH) appoints Kevin Thornal as Group President for Global Businesses and the Americas, effective July 1, 2025. Thornal brings over 20 yea

PR NewswireWARSAW, Ind., May 22, 2025 WARSAW, Ind., May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that memb

Zimmer Biomet (ZBH) to present at Goldman Sachs 46th Annual Global Healthcare Conference. Presentation scheduled for June 9, 2025, at 9:20 a.m. ET. L

Insights into Mark Hillman (Trades, Portfolio)'s Strategic Moves in Q1 2025 Mark Hillman (Trades, Portfolio) recently submitted the 13F filing for the first qu

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take a look at where Zimmer Biomet Holdings, Inc. (NYSE:ZBH) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed better in 2025 compared to the broader market. […]

On May 12, 2025, Canaccord Genuity analyst William Plovanic released an updated report on Zimmer Biomet Holdings (ZBH), maintaining a "Hold" rating on the stock

Canaccord has revised its price target for Zimmer Biomet (ZBH), reducing it from $115 to $101 while maintaining a Hold rating on the company's shares. This adju

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Zimmer Biomet Holdings, Inc.

Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from C

On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community.

Citizens JMP has revised its price target for Zimmer Biomet (ZBH), bringing it down from $140 to $125 while maintaining an Outperform rating. The company report

Strengths: Market leadership in orthopedic reconstructive products and robust R&D investments.Weaknesses: Rising operating expenses and potential integration c

Zimmer Biomet Holdings, Inc ZBH reported better-than-expected earnings for the first quarter on Monday. The company posted first-quarter adjusted EPS of $1.81,...